Remove Biopharma Remove Pharma Remove Safety
article thumbnail

EMA Committee’s Negative Opinion for Eisai Alzheimer’s Drug Focuses on Safety Risks

MedCity News

The post EMA Committee’s Negative Opinion for Eisai Alzheimer’s Drug Focuses on Safety Risks appeared first on MedCity News. The EMA’s Committee for Medicinal Products for Human Use expressed concern about brain complications associated with the Eisai Alzheimer’s drug, Leqembi.

Safety 93
article thumbnail

Preclinical Safety Signal Prompts FDA Clinical Hold on Neumora Schizophrenia Drug

MedCity News

The post Preclinical Safety Signal Prompts FDA Clinical Hold on Neumora Schizophrenia Drug appeared first on MedCity News. The FDA clinical hold keeps Neumora Therapeutics from catching up to the field of biopharmaceutical companies pursuing the same target for schizophrenia.

Safety 95
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Innovation in pharma manufacturing quality systems

European Pharmaceutical Review

For young biotechs, scaling up production brings green-field challenges, while for more established pharma a shift may be required to ensure that facilities are optimised for new ways of working. That is because of the relative expense of emerging therapies and the pressure on pricing for continuing product lines.

article thumbnail

FDA Calls for New Safety Warning for the Class of CAR T Cancer Therapies

MedCity News

Two months after announcing an inquiry into reports of new cancers in patients treated with CAR T-cell therapies, the FDA is directing makers of these therapies to add new safety warnings to product labels describing this risk. Companies have 30 calendar days to comply.

Safety 90
article thumbnail

Better Predicting Drug Safety Calms Quarrels Between Medical Needs & Regulatory Process

MedCity News

With animal testing requirements finally removed, the pharma industry and its constituents can hope for faster innovation. Human tissues, coupled with AI that can deal with terabytes of data will blow mice models out of the water.

Safety 98
article thumbnail

Eisai Alzheimer’s Drug Wins Full FDA Approval, But With Sterner Safety Alert

MedCity News

While the agency’s regulatory decision sets precedent for other Alzheimer’s drugs, it also flags serious safety risks. Six months after Esai Alzheimer’s disease drug Leqembi received accelerated FDA approval, the agency has awarded the drug full approval.

Safety 83
article thumbnail

FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in Decades

MedCity News

Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety. The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics.

FDA 103